This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG). The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce.
Zimmer Biomet (ZBH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.84% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Agilent (A) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strong Segmental Performance to Drive Stryker's Q1 Earnings?
by Zacks Equity Research
SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will BAX's Q1 Earnings Improve Following Transformation Completion?
by Zacks Equity Research
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
Are Options Traders Betting on a Big Move in Agilent Technologies Stock?
by Zacks Equity Research
Investors need to pay close attention to A stock based on the movements in the options market lately.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Agilent (A) Down 6.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Unlocking Agilent (A) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Agilent Q1 Earnings Beat Estimates, Stock Falls on Cautious FY25 View
by Zacks Equity Research
A's first-quarter fiscal 2025 results benefit from strong LC & services, but margin contraction raises investor concerns.
Agilent (A) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Agilent (A) give a sense of how its business performed in the quarter ended January 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Agilent Technologies (A) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Agilent (A) delivered earnings and revenue surprises of 3.15% and 0.86%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
QuantumSi Set to Report Q4 Earnings: Buy, Sell or Hold the Stock?
by Nilanshi Mukherjee
QSI's fourth-quarter performance is expected to have benefited from year-end capital spending and new product launches despite competition and stretched valuation.
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.
What Analyst Projections for Key Metrics Reveal About Agilent (A) Q1 Earnings
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Agilent (A), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended January 2025.
Agilent Rises 11% in a Year: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
A faces challenges with slowing end-market demand and regulatory hurdles in China, raising growth concerns.
Agilent (A) Up 1.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Agilent (A) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agilent (A) stock based on the movements in the options market lately.
Agilent Gains 5% in a Month: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
A's shares ride on the bright performance of the Agilent CrossLab Group segment and strategic acquisitions.
International Markets and Agilent (A): A Deep Dive for Investors
by Zacks Equity Research
Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Agilent Q4 Earnings Surpass Estimates, Revenues Increase Y/Y
by Zacks Equity Research
A's fourth-quarter 2024 results benefit from strong demand in the ACG segment. However, declining sales in the Americas and China markets raise concerns.
Agilent (A) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended October 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.